Previous 10 | Next 10 |
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
The following slide deck was published by Acorda Therapeutics, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Acorda Therapeutics, Inc. 2022 Q1 - Results - Earnings Call Presentation
Start Time: 16:30 End Time: 17:02 Acorda Therapeutics, Inc. (ACOR) Q1 2022 Earnings Conference Call May 11, 2022, 16:30 PM ET Company Participants Ron Cohen - Founder, President and CEO Mike Gesser - CFO Tierney Saccavino - EVP, Corporate Communications Conference Call Participants Muzamil Sa...
The commercial-stage biotech, Acorda Therapeutics (NASDAQ:ACOR), and South American pharma company, Biopas Laboratories announced an agreement on Wednesday to commercialize Acorda’s (ACOR) Parkinson's disease therapy Inbrija in certain Latin American countries. Accordingly, Biopas will...
Acorda Therapeutics press release (NASDAQ:ACOR): Q1 Non-GAAP EPS of -$1.66. Revenue of $22.53M (-21.9% Y/Y). INBRIJA (levodopa inhalation powder) Q1 2022 net revenue of $3.7 million; 26% decrease from Q1 2021 AMPYRA (dalfampridine) Q1 2022 net revenue of $14.9 million; 27% decr...
Acorda Therapeutics, Inc. (Nasdaq: ACOR) and Biopas Laboratories today announced that they have entered into distribution and supply agreements to commercialize INBRIJA ® in Latin America. INBRIJA is indicated in the United States for the intermittent treatment of episodic moto...
INBRIJA ® (levodopa inhalation powder) Q1 2022 net revenue of $3.7 million; 26% decrease from Q1 2021 AMPYRA ® (dalfampridine) Q1 2022 net revenue of $14.9 million; 27% decrease from Q1 2021 2022 AMPYRA net sales guidance reiterated at $68-$78 million ...
ACOR, ADMA, APP, ASM, ASND, ASYS, ATCO, BAK, BMBL, BROS, BYND, CLPT, CLSD, CPA, CPNG, CYCC, DIS, DOX, ENVX, FLNC, FOSL, FSM, GAIN, GBDC, ICAD, KGC, LGO, LKCO, LTBR, MBII, METC, MFC, MQ, MRAM, MYO, NEON, NOAH, OCX, ONTX, OR, OTRK, PAAS, PAYS, PSTL, OTCPK:PWCDF, RIVN, SAND, SCM, SCTL, SLF, SMTS...
Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a webcast/conference call in conjunction with its first quarter 2022 update and financial results on Wednesday, May 11 at 4:30 p.m. ET. To participate in the Webcast, please use the following pre-registration link: https://e...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
News, Short Squeeze, Breakout and More Instantly...
Acorda Therapeutics Inc. Company Name:
ACOR Stock Symbol:
NASDAQ Market:
Acorda Therapeutics Inc. Website:
A look at the top 10 most actives in the United States Verb Technology Company Inc. (VERB) rose 11.3% to $0.2025 on volume of 40,515,259 shares Rallybio Corporation (RLYB) rose 80.4% to $2.9401 on volume of 39,492,767 shares Trio Petroleum Corp. (TPET) rose 36.3% to $0.2499 on volume of 3...
A look at the top 10 most actives in the United States Selina Hospitality PLC (SLNA) rose 28.8% to $0.0515 on volume of 62,068,605 shares Laser Photonics Corporation (LASE) rose 172.7% to $3.9 on volume of 54,588,758 shares WiSA Technologies Inc. (WISA) fell 6.1% to $0.0217 on volume of 2...
Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that Nasdaq Stock Market ("Nasdaq") today notified the Company that it will suspend trading in and delist the Company's common stock, effective with the opening of business on April 12, 2024. The notice follows the Company's April 1, 2024 announc...